个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yang Yang[1] ; Tan Lijie[2] ; Hu Jian[3] ; Li Yin[4] ; Mao Yousheng[4] ; Tian Ziqiang[5] ; Zhang Baihua[6] ; Ma Jianqun[7] ; Li Hecheng[8] ; Chen Chun[9] ; Chen Keneng[10] ; Han Yongtao[11] ; Chen Longqi[12] ; Liu Junfeng[5] ; Yu Bentong[13] ; Yu Zhentao[14,15,*2] ; Li Zhigang[1,*1] ; the Esophageal Cancer Committee of Chinese Anti-Cancer Association ;
机构： [1]Department of Thoracic Surgery, Shanghai ChestHospital, Shanghai Jiao Tong University, Shanghai, P.R.China, [2]Department of Thoracic Surgery, Zhongshan Hospital Affiliated to Fudan University, Shanghai, P. R. China, [3]Department of Thoracic Surgery, The First AffiliatedHospital, Zhejiang University, School of Medicine,Zhejiang, P. R. China, [4]Department of Thoracic Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, P. R. China, [5]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, P. R. China, [6]Department of Thoracic Surgery, Hunan Cancer Hospital, Changsha, P. R. China, [7]Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, P. R. China, [8]Department of Thoracic Surgery, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China, [9]Department of Thoracic Surgery, FujianMedical University UnionHospital, Fuzhou, P. R. China, [10]Department of Thoracic Surgery, BeijingCancer Hospital, Beijing, P. R. China, [11]Department of Thoracic Surgery, Sichuan Cancer Hospital, Chengdu, P. R. China, [12]Department of Thoracic Surgery, West China Hospital of Sichuan University, Chengdu, P. R. China, [13]Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, P. R. China, [14]Department of Thoracic Surgery, Tianjin Medical University Cancer Hospital, Tianjin, P. R. China [15]Department of Thoracic Surgery, Cancer Hospital ChineseAcademy of Medical Sciences, Shenzhen Center, Shenzhen, P. R. China
出处：
DOI： 10.1093/dote/doac031
ISSN：

关键词： esophageal cancer immune checkpoint inhibitors neoadjuvant therapy

摘要：
Immune checkpoint inhibitors (ICIs) have shown a powerful benefit in the neoadjuvant therapy for esophageal cancer, but evidence for its safety and efficacy is limited and may not reflect real-world practice. We retrospectively reviewed the database of treatment-naive patients from 15 esophageal cancer centers in China who received ICIs as neoadjuvant treatment for locally advanced esophageal cancer from May 2019 to December 2020. The primary endpoints were rate and severity of treatment-related adverse events (TRAEs) and immune-related adverse events (irAEs). Secondary endpoints included pathologically complete response (pCR) rate, R0 resection rate, mortality and morbidity. Among the 370 patients, 311 (84.1%) were male with a median age of 63 (range: 30-81) years and stage III or IVa disease accounted for 84.1% of these patients. A total of 299 (80.8%) patients were treated with ICIs and chemotherapy. TRAEs were observed in 199 (53.8%) patients with low severity (grade 1-2, 39.2%; grade 3-4, 13.2%; grade 5, 1.4%), and irAEs occurred in 24.3% of patients and were mostly of grade 1-2 severity (21.1%). A total of 341 (92.2%) patients had received surgery and R0 resection was achieved in 333 (97.7%) patients. The local pCR rate in primary tumor was 34.6%, including 25.8% of ypT0N0 and 8.8% of ypT0N+. The rate of postoperative complications was 41.4% and grade 3 or higher complications occurred in 35 (10.3%) patients. No death was observed within 30 days after surgery, and three patients (0.9%) died within 90 days postoperatively. This study shows acceptable toxicity of neoadjuvant immunotherapy for locally advanced esophageal cancer in real-world data. Long-term survival results are pending for further investigations.© The Author(s) 2022. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

基金：
This study was energetically supported by the Esophageal Cancer Committee of Chinese Anti- Cancer Association and all participating institutions.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 3 区 医学
小类 | 4 区 胃肠肝病学
最新[2023]版：
大类 | 3 区 医学
小类 | 4 区 胃肠肝病学
JCR分区：
出版当年[2022]版：
Q4 GASTROENTEROLOGY & HEPATOLOGY
最新[2023]版：
Q3 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Thoracic Surgery, Shanghai ChestHospital, Shanghai Jiao Tong University, Shanghai, P.R.China,
通讯作者：
通讯机构： [1]Department of Thoracic Surgery, Shanghai ChestHospital, Shanghai Jiao Tong University, Shanghai, P.R.China, [14]Department of Thoracic Surgery, Tianjin Medical University Cancer Hospital, Tianjin, P. R. China [15]Department of Thoracic Surgery, Cancer Hospital ChineseAcademy of Medical Sciences, Shenzhen Center, Shenzhen, P. R. China [*1]Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China. [*2]Department of Thoracic Surgery, Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen 518116, China.
推荐引用方式(GB/T 7714)：
Yang Yang,Tan Lijie,Hu Jian,et al.Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China.[J].DISEASES OF THE ESOPHAGUS.2022,35(11):doi:10.1093/dote/doac031.
APA：
Yang Yang,Tan Lijie,Hu Jian,Li Yin,Mao Yousheng...&the Esophageal Cancer Committee of Chinese Anti-Cancer Association.(2022).Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China..DISEASES OF THE ESOPHAGUS,35,(11)
MLA：
Yang Yang,et al."Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China.".DISEASES OF THE ESOPHAGUS 35..11(2022)

相关文献

[1]Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers [2]Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. [3]The experience of immune checkpoint inhibitors in Chinese patients with metastatic melanoma: a retrospective case series [4]The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. [5]治疗药物浓度监测在免疫检查点抑制剂应用中的研究进展 [6]特瑞普利单抗致stevens-johnson综合征 [7]The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. [8]EZH1/2 alteration as a potential biomarker for immune checkpoint inhibitors across multiple cancer types [9]Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors [10]Exploring the most appropriate primary endpoint of immune checkpoint inhibitors for previously treated advanced solid cancers

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号